8-KEarnings & ResultsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 9, 2023)

Filed January 9, 2023For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. has reported preliminary financial results for the fourth quarter and full year 2022, demonstrating continued revenue growth from its key therapeutic products. For the full year 2022, global net product revenues are estimated to be approximately $894 million, with fourth quarter revenues reaching approximately $262 million. These figures encompass revenues from ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®, indicating strong commercial uptake and progress in market penetration for these treatments. Furthermore, the Company anticipates a robust financial position, with preliminary cash, cash equivalents, and marketable securities of approximately $2.2 billion as of December 31, 2022. This healthy cash balance provides Alnylam with significant financial flexibility for future research and development, potential business development opportunities, and continued commercial expansion. Investors should note that these results are preliminary and unaudited, with final audited results expected in February 2023.

Key Highlights

  • 1Preliminary full year 2022 global net product revenues estimated at approximately $894 million.
  • 2Preliminary fourth quarter 2022 global net product revenues estimated at approximately $262 million.
  • 3Revenues are driven by ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®.
  • 4Preliminary cash, cash equivalents, and marketable securities stood at approximately $2.2 billion as of December 31, 2022.
  • 5These preliminary results indicate strong commercial performance and a solid financial footing for Alnylam.
  • 6Final audited financial results are expected to be announced in February 2023.

Frequently Asked Questions

The reported revenues are generated from Alnylam's key therapeutic products: ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), and OXLUMO® (lumasiran).

No, the financial figures provided in this 8-K filing are preliminary and unaudited. They are subject to adjustment and will be finalized and audited before Alnylam announces its complete financial results, which are expected in February 2023.

Alnylam Pharmaceuticals estimates that its cash, cash equivalents, and marketable securities totaled approximately $2.2 billion as of December 31, 2022.

These preliminary results are significant as they indicate strong commercial progress and revenue growth from Alnylam's key products, as well as a substantial cash reserve. This suggests positive momentum for the company heading into 2023.